SI-BONE, Inc. SIBN
23.16 USD -0.25 (-1.07%)
Regular-session close
23.16 0.00 0.00%
After hours · Nov 17, 4:21 PM ET
22.94 Day range 23.46
11.48 52-week range 25.92
- YTD
- +17.44%
- 1 year
- +29.24%
News
zacks.com Are You Looking for a Top Momentum Pick? Why Si-Bone (SIBN) is a Great Choice Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
seekingalpha.com SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript SI-BONE, Inc. (SIBN) Presents at 2026 UBS Global Healthcare Conference Transcript
zacks.com SiBone (SIBN) Hit a 52 Week High, Can the Run Continue? Si-Bone (SIBN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.benzinga.com TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $23 TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $20 to $23.
benzinga.com Needham Maintains Buy on SI-BONE, Lowers Price Target to $26 Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and lowers the price target from $27 to $26.
seekingalpha.com SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q3 2026 Earnings Call Transcript
marketbeat.com SiBone Q3 Earnings Call Highlights SiBone NASDAQ: SIBN reported third-quarter 2026 revenue growth of 14.5% as procedure demand accelerated, active physician adoption expanded and profitability improved. The company said it is building…
zacks.com Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
benzinga.com SI-BONE Q3 2026 Earnings Call Transcript SI-BONE (NASDAQ:SIBN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com SI-BONE Affirms FY2026 Sales Guidance of $231.000M-$233.000M vs $232.024M Est SI-BONE (NASDAQ:SIBN) affirms FY2026 sales outlook from $231.000 million-$233.000 million to $231.000 million-$233.000 million vs $232.024 million estimate.
benzinga.com SI-BONE Q3 EPS $(0.08) Beats $(0.13) Estimate, Sales $55.704M Beat $55.404M Estimate SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.13) by 33.33 percent. This is a 27.27 percent increase over losses of $(0.11) per…
globenewswire.com SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance Delivered ~20 % U.S. procedure volume growth in the third quarter Third Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $55.7 million,…
globenewswire.com SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026 SAN JOSE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone,…
globenewswire.com SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026 SAN JOSE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ: SIBN), a global leader in developing procedural solutions to address clinical challenges associated with compromised bone,…
gurufocus.com Is SI-BONE Inc (SIBN) Overvalued After 3.8% Rally? GF Value Says Overvalued On October 12, 2026, SI-BONE Inc (SIBN) shares rose 3.8% to a current price of $20.10. This movement comes amid a 52-week range that saw a high of $21.89 and a
defenseworld.net Analyzing SiBone (NASDAQ:SIBN) & Integer (NYSE:ITGR) Integer (NYSE: ITGR - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the…
globenewswire.com SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density bone FDA Breakthrough Device Designated (BDD) platform engineered for durable fixation in low density…
seekingalpha.com SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript SI-BONE, Inc. (SIBN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026 SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised…
zacks.com Si-Bone (SIBN) is a Great Momentum Stock: Should You Buy? Does Si-Bone (SIBN) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 25.25%: Here's is How to Trade The mean of analysts' price targets for Si-Bone (SIBN) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among…
zacks.com Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect? The consensus price target hints at a 38.6% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate…
defenseworld.net SiBone Q2 Earnings Call Highlights SiBone (NASDAQ: SIBN) reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss as procedure volumes increased across its U.S. business and international demand rose for its…
seekingalpha.com SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript
zacks.com Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates Si-Bone (SIBN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.14 per share a year ago.
